JMJD6 and non-small cell lung carcinoma: To confirm the results analyzed based on TCGA data, we further conducted IHC analyses in a NSCLC patients cohort comprised of 188 NSCLC patients (90 LUSC patients and 98 LUAD patients) to evaluate the clinical significance of JMJD6 in NSCLC.